Vectura Limited v. GlaxoSmithKline LLC
1:16-cv-00638
Overview
Parties
Defendant
Glaxo Group Limited NPE (University / Research)
Represented By
4 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
GlaxoSmithKline LLC NPE (University / Research)
Represented By
4 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Plaintiff
Vectura Limited NPE (University / Research)
Represented By
8 Attorneys ListedRichards, Layton & Finger
Richards, Layton & Finger, 920 North King Street
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 11 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 8,303,991 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 8,956,661 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 9,931,304 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 9,962,338 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 10,973,771 B2 | US Continuation / Sibling | View Official Patent → |
| 🇬🇧 United Kingdom | GB 0029261 | United Kingdom Counterpart | View Official Patent → |
| 🇬🇧 United Kingdom | GB 0030946 | United Kingdom Counterpart | View Official Patent → |
| 🌐 PCT International (WIPO) | WO 2001076575 A2 | PCT World Application | View Official Patent → |
| 🇬🇧 United Kingdom | GB 0124010 | United Kingdom Counterpart | View Official Patent → |
| 🌐 PCT International (WIPO) | WO 2002043701 A2 | PCT World Application | View Official Patent → |
| 🇺🇸 United States | US 7,736,670 B2 | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 3 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8303991
Method of making particles for use in a pharmaceutical composition
|
Filed: 2010-04-26
Issued: 2012-11-06
|
Active (3.4 yrs remaining)
Expires: 2030-04-26
|
|
|
US8435567
Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation
|
Filed: 2011-10-07
Issued: 2013-05-07
|
Active (4.9 yrs remaining)
Expires: 2031-10-07
|
|
|
US8956661
Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof
|
Filed: 2012-09-20
Issued: 2015-02-17
|
Active (5.8 yrs remaining)
Expires: 2032-09-20
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
Standard Statutory Term — No obviousness-type double patenting truncation noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).
Procedural Motions & Interlocutory Orders
Total Motions
87
Dispositive
31
Granted
5
Denied
2
Pending / Review
67
Motions by Category
Key Dispositive Motions & Rulings